PURPOSE: The aim of this study is to identify the potential tumor markers that function in carcinogenesis and tumor progression, thus providing important diagnostic and prognostic information. EXPERIMENTAL DESIGN: We performed 2-D gel electrophoresis and MALDI-TOF MS to investigate the differentially expressed proteins in 25 papillary thyroid carcinoma tissues. For validation of candidate proteins and investigation of clinical significance, we performed Western, Northern blot analysis and immunohistochemical staining. RESULTS: Our proteomic analyses revealed significantly decreased annexin A3 expression in papillary thyroid carcinoma at both the protein and mRNA levels, compared with normal thyroid tissue. ANXA3 immunoreactivity was not significantly correlated with lymph node metastasis, multifocality, capsular invasion or perithyroidal extension in thyroid cancer. However, the tumor subgroup with a lymph node metastasis score of >3 displayed significantly lower ANXA3 expression than did subgroups with negative and ≤3 scores (p=0.001). Moreover, ANXA3 expression was markedly lower in large tumors (>1 cm in diameter) than in microcarcinomas (p=0.001). CONCLUSION AND CLINICAL RELEVANCE: Decreased expression of ANXA3 in papillary thyroid cancer supports the idea that ANXA3 may be an effective marker of microcarcinoma, and a negative predictor of papillary thyroid cancer progression.
PURPOSE: The aim of this study is to identify the potential tumor markers that function in carcinogenesis and tumor progression, thus providing important diagnostic and prognostic information. EXPERIMENTAL DESIGN: We performed 2-D gel electrophoresis and MALDI-TOF MS to investigate the differentially expressed proteins in 25 papillary thyroid carcinoma tissues. For validation of candidate proteins and investigation of clinical significance, we performed Western, Northern blot analysis and immunohistochemical staining. RESULTS: Our proteomic analyses revealed significantly decreased annexin A3 expression in papillary thyroid carcinoma at both the protein and mRNA levels, compared with normal thyroid tissue. ANXA3 immunoreactivity was not significantly correlated with lymph node metastasis, multifocality, capsular invasion or perithyroidal extension in thyroid cancer. However, the tumor subgroup with a lymph node metastasis score of >3 displayed significantly lower ANXA3 expression than did subgroups with negative and ≤3 scores (p=0.001). Moreover, ANXA3 expression was markedly lower in large tumors (>1 cm in diameter) than in microcarcinomas (p=0.001). CONCLUSION AND CLINICAL RELEVANCE: Decreased expression of ANXA3 in papillary thyroid cancer supports the idea that ANXA3 may be an effective marker of microcarcinoma, and a negative predictor of papillary thyroid cancer progression.
Authors: Xiuzhen Fan; Jianling Wang; Kizhake V Soman; G A S Ansari; M Firoze Khan Journal: Toxicol Appl Pharmacol Date: 2011-06-15 Impact factor: 4.219
Authors: Marta Sarquis; Debora C Moraes; Luciana Bastos-Rodrigues; Pedro G Azevedo; Adauto V Ramos; Fabiana Versiani Reis; Paula V Dande; Isabela Paim; Eitan Friedman; Luiz De Marco Journal: Endocr Pathol Date: 2020-03 Impact factor: 3.943
Authors: Andrii Dinets; Maria Pernemalm; Hanna Kjellin; Vitalijs Sviatoha; Anastasios Sofiadis; C Christofer Juhlin; Jan Zedenius; Catharina Larsson; Janne Lehtiö; Anders Höög Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240
Authors: Bashar Zeidan; Thomas R Jackson; Samantha E T Larkin; Ramsey I Cutress; Gary R Coulton; Margaret Ashton-Key; Nick Murray; Graham Packham; Vassilis Gorgoulis; Spiros D Garbis; Paul A Townsend Journal: Oncotarget Date: 2015-08-28
Authors: Zsófia Pénzváltó; Bálint Tegze; A Marcell Szász; Zsófia Sztupinszki; István Likó; Attila Szendrői; Reinhold Schäfer; Balázs Győrffy Journal: PLoS One Date: 2013-03-29 Impact factor: 3.240